Skip to main content
Equibles
FNCHQ logo

FNCHQ · Finch Therapeutics Group, Inc. · Metrics

Track FNCHQ — free

Use FNCHQ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FNCHQ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.35 At close · Sep 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2024

Substantial doubt about the company's ability to continue as a going concern.

“due to the consideration of certain qualitative factors, including the Company's recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and uncertainty around its ability to successfully realize the full value of its intellectual property estate and other assets, the Company has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 13, 2024
Market Cap
$16.62M
Shares
1.61M
Volume · Sep 23 5800 Avg daily vol (3M) 2195

FNCHQ metrics

57 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.35
Market cap
$16.62M

Price action

23 metrics
Price change (1W)
+0.0%
Price change (30D)
—
Price change (3M)
+11.3%
Price change (6M)
+20.3%
Price change (YTD)
-23.3%
Price change (1Y)
-15.2%
Trailing year
Price change (5Y)
—
52-week high
$14.56
52-week low
$6.21
Change from 52-week high
-28.9%
Change from 52-week low
+66.7%
Annualized volatility
78.3%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.2
RSI (14D)
57.9
Price vs SMA 50
+9.1%
Price vs SMA 200
-10.2%
Avg volume (3M)
2,195
Relative volume
2.6
Average dollar volume
$22,234

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.61M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.2
reciprocal yield 85.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-85.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
-121.1×
EV / revenue historical average (5Y)
-121.1×
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2022-05-16

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$19.50M
Net income (TTM)
−$14.17M
Trailing 12 months
Diluted EPS (TTM)
$-8.49
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-12.15
EBITDA per diluted share (TTM)
$-12.03
Net income per diluted share (TTM)
$-8.82
Operating cash flow per diluted share (TTM)
$-11.25
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.00
Stock compensation per diluted share (TTM)
$0.31
Book value per share
$14.25

Growth

11 metrics
Revenue growth YoY
-87.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.1%
Year over year · more shares
Revenue CAGR (3Y)
-76.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-99.6%
Return on assets
-31.1%
Debt / equity
0.0
Current ratio
3.9
EBITDA (TTM)
−$19.32M
Free cash flow (TTM)
—
Quick ratio
3.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$25.12M
Latest balance sheet
Cash & equivalents
$16.04M
Total assets
$45.58M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$18.05M
Capital expenditures (TTM)
—
R&D (TTM)
$0
SG&A (TTM)
—
Stock compensation (TTM)
$492,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1733257 CUSIP 31773D200 Visit website